Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2, first line trial of CRDF-004

Next Previous
Trial Profile

Phase 2, first line trial of CRDF-004

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CRDF 004 (Primary) ; Onvansertib (Primary) ; Bevacizumab
  • Indications Colorectal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 29 Feb 2024 According to Cardiff Oncology media release, Pfizer Ignite is conducting the clinical execution of this study.
  • 29 Feb 2024 According to Cardiff Oncology media release, interim topline results are expected in mid-2024. Contingent upon the results, Cardiff Oncology will initiate a Phase 3, randomized trial, CRDF-005, with registrational intent.
  • 29 Feb 2024 According to Cardiff Oncology media release, first patient has been dosed in this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top